MaxCyte, Inc. Total Voting Rights (0291Y)
November 30 2017 - 10:26AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 0291Y
MaxCyte, Inc.
30 November 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Maryland, USA - 30 November 2017: MaxCyte (LSE: MXCT, MXCR)
announces that, following an exercise of options, 41,121 new shares
of common stock of $0.01 each in the Company (the "Common Stock")
were issued from the blocklisting facility granted 5 May 2017.
The total issued stock capital of the Company has consequently
increased to 50,878,083 shares of Common Stock. There is no Common
Stock held in treasury. Therefore, the total number of voting
rights in the Company is 50,878,083. Stockholders in the Company
may use this figure as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the capital of the
Company.
The Company also announces that, in accordance with the
Company's intention disclosed in its circular dated 31 March 2017,
the Company has effected the transfer of Common Stock held by an
affiliate to its restricted line of Common Stock, with such stock
to continue to be held by such affiliate in certificated form.
Following the issue of Common Stock from the blocklisting
facility and following the effected transfer of the certain
affiliate's stock to the restricted line, the number of
unrestricted shares of Common Stock trading under the symbol 'MXCT'
is 35,364,975 and the number of restricted shares of Common Stock
trading under the symbol 'MXCR' is 15,513,108. The number of Common
Stock capable of being issued under the blocklisting facility is
936,444 shares of Common Stock.
- ENDS -
For further information please contact:
MaxCyte, Inc. +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving
the acceleration of the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
platform to biopharmaceutical partners engaged in drug discovery
and development, biomanufacturing, and cell therapy, including gene
editing and immuno-oncology. With its robust delivery platform,
MaxCyte's team of scientific experts helps its partners to unlock
their product potential and solve problems. This platform allows
for the engineering of nearly all cell types, including human
primary cells, with any molecule, at any scale. It also provides a
high degree of consistency and minimal cell disturbance, thereby
facilitating rapid, large-scale, clinical and commercial grade cell
engineering in a non-viral system and with low-toxicity concerns.
The Company's cell-engineering platform is FDA-accredited,
providing MaxCyte's customers and partners with an established
regulatory path to commercialize cell-based medicines. MaxCyte is
also developing CARMA, its proprietary, breakthrough platform in
immuno-oncology, to rapidly manufacture CAR therapies for a broad
range of cancer indications, including solid tumours where existing
CAR-T approaches face significant challenges.
For more information, visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVROKKDBPBDDDDN
(END) Dow Jones Newswires
November 30, 2017 10:26 ET (15:26 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2024 to Jun 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2023 to Jun 2024